30.17
Ionis Pharmaceuticals Inc (IONS) 最新ニュース
Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts - Benzinga
Redburn Atlantic Initiates Ionis Pharmaceuticals at Neutral With $39 Price Target - MarketScreener
Ionis to present at upcoming investor conferences - The Joplin Globe
Ionis Secures Triple Conference Spotlight: Key Investor Events Announced for Spring 2025 - Stock Titan
Redburn initiates Ionis stock with Neutral, sets $39 target - Investing.com India
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi - MSN
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. - MSN
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
RNA Biotechs: Current State And Outlook - Seeking Alpha
Ionis and Sobi agree on olezarsen commercialisation - Yahoo
Ionis licenses olezarsen to Sobi for global reach By Investing.com - Investing.com South Africa
Ionis Partners With Sobi to Commercialize Familial Chylomicronemia Syndrome Treatment Outside US - Marketscreener.com
Ionis Expands Partnership With SOBI To Include Olezarsen Commercialization Outside The U.S. - Marketscreener.com
Ionis licenses olezarsen to Sobi for global reach - Investing.com
First-Ever FCS Treatment: Ionis Expands Global Reach with Major Partnership Deal - Stock Titan
Is Ionis Pharmaceuticals, Inc. (IONS) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
12 Most Promising Biotech Stocks According to Wall Street Analysts - Insider Monkey
Ionis Pharmaceuticals’ SWOT analysis: RNA pioneer’s stock faces pivotal year - Investing.com
Ionis Rings the Opening Bell - Nasdaq
Ionis Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting - GlobeNewswire Inc.
Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S - simplywall.st
Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report? - Yahoo Finance Australia
Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Ionis Pharma - Barchart
Multiple System Atrophy Market to Reach New Heights in Growth - openPR
Familial Chylomicronemia Syndrome Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Spinocerebellar Ataxias Pipeline 2025: Therapies, MOA - openPR
Ionis Pharmaceuticals at UBS Virtual CNS Day: Neurology Pipeline Insights By Investing.com - Investing.com UK
Opinion: Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx and Neuren - BioSpace
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe - MSN
Retinitis Pigmentosa Pipeline 2024: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Biogen, Neurotech, Ionis Pharma, Nacuity Pharma, Allegro Ophthalmics - Barchart
Ionis Pharmaceuticals CEO Monia sells $4,524 in stock By Investing.com - Investing.com Australia
Charles Schwab Investment Management Inc. Purchases 38,420 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World
Chief Executive Officer Monia Brett P sold $4,525 worth of shares (140 units at $32.32), decreasing direct ownership by 0.08% to 180,980 units (SEC Form 4) - Quantisnow
Ionis Pharmaceuticals CEO Monia sells $4,524 in stock - Investing.com India
Ionis Gets Tryngolza Launch Cash From Ono Via Sapablursen License - Citeline
Ionis Pharmaceuticals at Barclays Conference: Strategic Growth and Partnerships By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - AOL
Ono earmarks $940m to gain rare blood cancer therapy from Ionis - Yahoo
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal - AOL
Ono partners with Ionis for sapablursen - The Pharma Letter
Ono pays $280M to license Ionis rare disease drug - BioPharma Dive
Oppenheimer maintains Outperform on Ionis, $78 target By Investing.com - Investing.com UK
Ionis out licenses blood disorder therapy to Ono in a deal worth up to $940M - MSN
Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono - Zacks Investment Research
Ionis Pharmaceuticals Enters Global License Agreement With Ono Pharmaceutical for Sapablursen - Marketscreener.com
Jones Financial Companies Lllp Has $326,000 Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Cut to $47.00 by Analysts at JPMorgan Chase & Co. - Defense World
大文字化:
|
ボリューム (24 時間):